Related references
Note: Only part of the references are listed.Clinical pattern and associations of oxaliplatin acute neurotoxicity
Andreas A. Argyriou et al.
CANCER (2013)
XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
Fanghui Ye et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
Kyung-Hun Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis
Zhi Peng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
A. A. Argyriou et al.
ANNALS OF ONCOLOGY (2012)
Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients
Hong-Hee Won et al.
CANCER (2012)
A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis
Daniele Campa et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity
Michele Basso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes
M. Inada et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pharmacogenetics of Oxaliplatin as Adjuvant Treatment in Colon Carcinoma Are Single Nucleotide Polymorphisms in GSTP1, ERCC1, and ERCC2 Good Predictive Markers?
Arantza Farina Sarasqueta et al.
MOLECULAR DIAGNOSIS & THERAPY (2011)
Temporal and Spatial Expression of Cyclin H in Rat Spinal Cord Injury
Gang Wu et al.
NEUROMOLECULAR MEDICINE (2011)
Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility
Susanna B. Park et al.
ONCOLOGIST (2011)
Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy
Masashi Kanai et al.
CANCER EPIDEMIOLOGY (2010)
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
Howard L. McLeod et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
Kyung Kee Baek et al.
CANCER RESEARCH AND TREATMENT (2010)
Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy
Dirk Theile et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array
D. M. Kweekel et al.
BRITISH JOURNAL OF CANCER (2009)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Liability of the Voltage-Gated Sodium Channel Gene SCN2A R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy
Andreas A. Argyriou et al.
ONCOLOGY (2009)
Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding
Lauren E. Ta et al.
NEUROTOXICOLOGY (2006)
CAK-cyclin-dependent activating kinase - A key kinase in cell cycle control and a target for drugs?
G Lolli et al.
CELL CYCLE (2005)
Share Paper
